anti aak1  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Cell Signaling Technology Inc anti aak1
    A) Kinome dendrogram overlayed with FOCUS cell kinases whose PPIs significantly change in response to AXL RNAi knockdown (BH-FDR < 0.05, n = 5). The PPI with the highest fold-change was used for potting. B) Ki-CCA interaction network of high confidence interactors (r > 0.6) for the <t>AAK1/BMP2K</t> kinase group identified across the 18-cell line panel. C) Abundance differences of AAK1/BMP2K network components between FOCUS WT/ AXL RNAi cells, and mesenchymal- like and epithelial-like cells of a 17 HCC line panel (kinobead/LC-MS data). * t-test significant, BH-FDR < 0.05. D) Abundance differences of AAK1/BMP2K complex components between human HCC tumor tissue and normal adjacent liver (kinobead/LC-MS data). * t-test significant, BH-FDR < 0.05.
    Anti Aak1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti aak1/product/Cell Signaling Technology Inc
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti aak1 - by Bioz Stars, 2023-01
    93/100 stars

    Images

    1) Product Images from "Multiplexed profiling of kinase interactomes quantifies cellular network plasticity"

    Article Title: Multiplexed profiling of kinase interactomes quantifies cellular network plasticity

    Journal: bioRxiv

    doi: 10.1101/2021.09.14.460283

    A) Kinome dendrogram overlayed with FOCUS cell kinases whose PPIs significantly change in response to AXL RNAi knockdown (BH-FDR < 0.05, n = 5). The PPI with the highest fold-change was used for potting. B) Ki-CCA interaction network of high confidence interactors (r > 0.6) for the AAK1/BMP2K kinase group identified across the 18-cell line panel. C) Abundance differences of AAK1/BMP2K network components between FOCUS WT/ AXL RNAi cells, and mesenchymal- like and epithelial-like cells of a 17 HCC line panel (kinobead/LC-MS data). * t-test significant, BH-FDR < 0.05. D) Abundance differences of AAK1/BMP2K complex components between human HCC tumor tissue and normal adjacent liver (kinobead/LC-MS data). * t-test significant, BH-FDR < 0.05.
    Figure Legend Snippet: A) Kinome dendrogram overlayed with FOCUS cell kinases whose PPIs significantly change in response to AXL RNAi knockdown (BH-FDR < 0.05, n = 5). The PPI with the highest fold-change was used for potting. B) Ki-CCA interaction network of high confidence interactors (r > 0.6) for the AAK1/BMP2K kinase group identified across the 18-cell line panel. C) Abundance differences of AAK1/BMP2K network components between FOCUS WT/ AXL RNAi cells, and mesenchymal- like and epithelial-like cells of a 17 HCC line panel (kinobead/LC-MS data). * t-test significant, BH-FDR < 0.05. D) Abundance differences of AAK1/BMP2K complex components between human HCC tumor tissue and normal adjacent liver (kinobead/LC-MS data). * t-test significant, BH-FDR < 0.05.

    Techniques Used: Liquid Chromatography with Mass Spectroscopy

    A) Kinobead/LC-MS soluble competition experiment using 1 µM of the selective AAK1 inhibitor LB-935509. Members of the AAK1/BMP2K PPI network are highlighted. B) Co-IP-MS experiments in FOCUS cells using antibodies targeting AAK1, RALBP1, and REPS1 validate the AAK1 complex’ identity. C) Western blot analysis of EMT markers in SNU387 and FOCUS RNAi lines. For analysis of the SKHep1 and SNU761 lines see . D) Kinobead/LC-MS profiling data of AAK1 complex RNAi lines showing that NF-kB and EMT kinases consistently decrease in expression in three out of four cell line models. E) Drug screen results demonstrating that AAK1 complex RNAi lines are up to 18-fold more sensitive to the CHEK1 and 2 inhibitors AZD-7762 and CHIR-124. F) Kinobead/LC-MS profiling from SKHep1 and SNU387 lines showing that AAK1 complex RNAi activates cell cycle-related kinases.
    Figure Legend Snippet: A) Kinobead/LC-MS soluble competition experiment using 1 µM of the selective AAK1 inhibitor LB-935509. Members of the AAK1/BMP2K PPI network are highlighted. B) Co-IP-MS experiments in FOCUS cells using antibodies targeting AAK1, RALBP1, and REPS1 validate the AAK1 complex’ identity. C) Western blot analysis of EMT markers in SNU387 and FOCUS RNAi lines. For analysis of the SKHep1 and SNU761 lines see . D) Kinobead/LC-MS profiling data of AAK1 complex RNAi lines showing that NF-kB and EMT kinases consistently decrease in expression in three out of four cell line models. E) Drug screen results demonstrating that AAK1 complex RNAi lines are up to 18-fold more sensitive to the CHEK1 and 2 inhibitors AZD-7762 and CHIR-124. F) Kinobead/LC-MS profiling from SKHep1 and SNU387 lines showing that AAK1 complex RNAi activates cell cycle-related kinases.

    Techniques Used: Liquid Chromatography with Mass Spectroscopy, Co-Immunoprecipitation Assay, Western Blot, Expressing

    A) qPCR analysis of AAK1 complex RNAi lines, validating successful knockdown. B) Kinobead/LC-MS analysis of AAK1 complex RNAi lines, validating successful knockdown. C) Immunoblot analysis of AAK1 complex RNAi lines, validating successful knockdown. REPS2 blots not shown because the antibody used is likely not specific.
    Figure Legend Snippet: A) qPCR analysis of AAK1 complex RNAi lines, validating successful knockdown. B) Kinobead/LC-MS analysis of AAK1 complex RNAi lines, validating successful knockdown. C) Immunoblot analysis of AAK1 complex RNAi lines, validating successful knockdown. REPS2 blots not shown because the antibody used is likely not specific.

    Techniques Used: Liquid Chromatography with Mass Spectroscopy, Western Blot

    Immunoblot analysis of EMT marker expression in AAK1 complex RNAi cell lines.
    Figure Legend Snippet: Immunoblot analysis of EMT marker expression in AAK1 complex RNAi cell lines.

    Techniques Used: Western Blot, Marker, Expressing

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93
    Cell Signaling Technology Inc anti aak1
    A) Kinome dendrogram overlayed with FOCUS cell kinases whose PPIs significantly change in response to AXL RNAi knockdown (BH-FDR < 0.05, n = 5). The PPI with the highest fold-change was used for potting. B) Ki-CCA interaction network of high confidence interactors (r > 0.6) for the <t>AAK1/BMP2K</t> kinase group identified across the 18-cell line panel. C) Abundance differences of AAK1/BMP2K network components between FOCUS WT/ AXL RNAi cells, and mesenchymal- like and epithelial-like cells of a 17 HCC line panel (kinobead/LC-MS data). * t-test significant, BH-FDR < 0.05. D) Abundance differences of AAK1/BMP2K complex components between human HCC tumor tissue and normal adjacent liver (kinobead/LC-MS data). * t-test significant, BH-FDR < 0.05.
    Anti Aak1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti aak1/product/Cell Signaling Technology Inc
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti aak1 - by Bioz Stars, 2023-01
    93/100 stars
      Buy from Supplier

    Image Search Results


    A) Kinome dendrogram overlayed with FOCUS cell kinases whose PPIs significantly change in response to AXL RNAi knockdown (BH-FDR < 0.05, n = 5). The PPI with the highest fold-change was used for potting. B) Ki-CCA interaction network of high confidence interactors (r > 0.6) for the AAK1/BMP2K kinase group identified across the 18-cell line panel. C) Abundance differences of AAK1/BMP2K network components between FOCUS WT/ AXL RNAi cells, and mesenchymal- like and epithelial-like cells of a 17 HCC line panel (kinobead/LC-MS data). * t-test significant, BH-FDR < 0.05. D) Abundance differences of AAK1/BMP2K complex components between human HCC tumor tissue and normal adjacent liver (kinobead/LC-MS data). * t-test significant, BH-FDR < 0.05.

    Journal: bioRxiv

    Article Title: Multiplexed profiling of kinase interactomes quantifies cellular network plasticity

    doi: 10.1101/2021.09.14.460283

    Figure Lengend Snippet: A) Kinome dendrogram overlayed with FOCUS cell kinases whose PPIs significantly change in response to AXL RNAi knockdown (BH-FDR < 0.05, n = 5). The PPI with the highest fold-change was used for potting. B) Ki-CCA interaction network of high confidence interactors (r > 0.6) for the AAK1/BMP2K kinase group identified across the 18-cell line panel. C) Abundance differences of AAK1/BMP2K network components between FOCUS WT/ AXL RNAi cells, and mesenchymal- like and epithelial-like cells of a 17 HCC line panel (kinobead/LC-MS data). * t-test significant, BH-FDR < 0.05. D) Abundance differences of AAK1/BMP2K complex components between human HCC tumor tissue and normal adjacent liver (kinobead/LC-MS data). * t-test significant, BH-FDR < 0.05.

    Article Snippet: Antibodies used were anti-E-cadherin (24E10, Cell Signaling Technology, CST, Cat # 3195), anti-AXL (C89E7, CST, Cat # 8661), anti-Snail (C15D3, CST, Cat # 3879), anti-ZEB1 (E2G6Y, CST, Cat # 70512), anti-CD44 (E7K2Y, CST, Cat # 37259), anti-GAPDH HRP conjugate (D16H11, CST, Cat # 8884), anti-AAK1 (E8M3P, CST, Cat # 61527), anti-RALBP1 (D87H8, CST, Cat # 5739), and anti-REPS1 (D6F4, CST, Cat # 6404).

    Techniques: Liquid Chromatography with Mass Spectroscopy

    A) Kinobead/LC-MS soluble competition experiment using 1 µM of the selective AAK1 inhibitor LB-935509. Members of the AAK1/BMP2K PPI network are highlighted. B) Co-IP-MS experiments in FOCUS cells using antibodies targeting AAK1, RALBP1, and REPS1 validate the AAK1 complex’ identity. C) Western blot analysis of EMT markers in SNU387 and FOCUS RNAi lines. For analysis of the SKHep1 and SNU761 lines see . D) Kinobead/LC-MS profiling data of AAK1 complex RNAi lines showing that NF-kB and EMT kinases consistently decrease in expression in three out of four cell line models. E) Drug screen results demonstrating that AAK1 complex RNAi lines are up to 18-fold more sensitive to the CHEK1 and 2 inhibitors AZD-7762 and CHIR-124. F) Kinobead/LC-MS profiling from SKHep1 and SNU387 lines showing that AAK1 complex RNAi activates cell cycle-related kinases.

    Journal: bioRxiv

    Article Title: Multiplexed profiling of kinase interactomes quantifies cellular network plasticity

    doi: 10.1101/2021.09.14.460283

    Figure Lengend Snippet: A) Kinobead/LC-MS soluble competition experiment using 1 µM of the selective AAK1 inhibitor LB-935509. Members of the AAK1/BMP2K PPI network are highlighted. B) Co-IP-MS experiments in FOCUS cells using antibodies targeting AAK1, RALBP1, and REPS1 validate the AAK1 complex’ identity. C) Western blot analysis of EMT markers in SNU387 and FOCUS RNAi lines. For analysis of the SKHep1 and SNU761 lines see . D) Kinobead/LC-MS profiling data of AAK1 complex RNAi lines showing that NF-kB and EMT kinases consistently decrease in expression in three out of four cell line models. E) Drug screen results demonstrating that AAK1 complex RNAi lines are up to 18-fold more sensitive to the CHEK1 and 2 inhibitors AZD-7762 and CHIR-124. F) Kinobead/LC-MS profiling from SKHep1 and SNU387 lines showing that AAK1 complex RNAi activates cell cycle-related kinases.

    Article Snippet: Antibodies used were anti-E-cadherin (24E10, Cell Signaling Technology, CST, Cat # 3195), anti-AXL (C89E7, CST, Cat # 8661), anti-Snail (C15D3, CST, Cat # 3879), anti-ZEB1 (E2G6Y, CST, Cat # 70512), anti-CD44 (E7K2Y, CST, Cat # 37259), anti-GAPDH HRP conjugate (D16H11, CST, Cat # 8884), anti-AAK1 (E8M3P, CST, Cat # 61527), anti-RALBP1 (D87H8, CST, Cat # 5739), and anti-REPS1 (D6F4, CST, Cat # 6404).

    Techniques: Liquid Chromatography with Mass Spectroscopy, Co-Immunoprecipitation Assay, Western Blot, Expressing

    A) qPCR analysis of AAK1 complex RNAi lines, validating successful knockdown. B) Kinobead/LC-MS analysis of AAK1 complex RNAi lines, validating successful knockdown. C) Immunoblot analysis of AAK1 complex RNAi lines, validating successful knockdown. REPS2 blots not shown because the antibody used is likely not specific.

    Journal: bioRxiv

    Article Title: Multiplexed profiling of kinase interactomes quantifies cellular network plasticity

    doi: 10.1101/2021.09.14.460283

    Figure Lengend Snippet: A) qPCR analysis of AAK1 complex RNAi lines, validating successful knockdown. B) Kinobead/LC-MS analysis of AAK1 complex RNAi lines, validating successful knockdown. C) Immunoblot analysis of AAK1 complex RNAi lines, validating successful knockdown. REPS2 blots not shown because the antibody used is likely not specific.

    Article Snippet: Antibodies used were anti-E-cadherin (24E10, Cell Signaling Technology, CST, Cat # 3195), anti-AXL (C89E7, CST, Cat # 8661), anti-Snail (C15D3, CST, Cat # 3879), anti-ZEB1 (E2G6Y, CST, Cat # 70512), anti-CD44 (E7K2Y, CST, Cat # 37259), anti-GAPDH HRP conjugate (D16H11, CST, Cat # 8884), anti-AAK1 (E8M3P, CST, Cat # 61527), anti-RALBP1 (D87H8, CST, Cat # 5739), and anti-REPS1 (D6F4, CST, Cat # 6404).

    Techniques: Liquid Chromatography with Mass Spectroscopy, Western Blot

    Immunoblot analysis of EMT marker expression in AAK1 complex RNAi cell lines.

    Journal: bioRxiv

    Article Title: Multiplexed profiling of kinase interactomes quantifies cellular network plasticity

    doi: 10.1101/2021.09.14.460283

    Figure Lengend Snippet: Immunoblot analysis of EMT marker expression in AAK1 complex RNAi cell lines.

    Article Snippet: Antibodies used were anti-E-cadherin (24E10, Cell Signaling Technology, CST, Cat # 3195), anti-AXL (C89E7, CST, Cat # 8661), anti-Snail (C15D3, CST, Cat # 3879), anti-ZEB1 (E2G6Y, CST, Cat # 70512), anti-CD44 (E7K2Y, CST, Cat # 37259), anti-GAPDH HRP conjugate (D16H11, CST, Cat # 8884), anti-AAK1 (E8M3P, CST, Cat # 61527), anti-RALBP1 (D87H8, CST, Cat # 5739), and anti-REPS1 (D6F4, CST, Cat # 6404).

    Techniques: Western Blot, Marker, Expressing